Details:
The results showed nearly 50% reduction in lung injury in the C21 group compared with the placebo group suggest that C21 could accelerate recovery and it is currently being evaluated in a phase 3 trial in COVID-19 patients.
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: C21
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the “protective arm” of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage.
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: C21
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2021
Details:
ATTRACT-3 is the pivotal trial in which C21, an angiotensin II type 2 receptor (AT2R) agonist, is tested for the treatment of COVID-19. C21 showed significantly reduced the extended need for supplemental oxygen therapy.
Lead Product(s): VP01
Therapeutic Area: Infections and Infectious Diseases Product Name: C21
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2021
Details:
The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chances of full recovery.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Kineret
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021
Details:
In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 infection.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Product Name: Kineret
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Hellenic Institute for the Study of Sepsis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Details:
Recipharm has reserved capacity to support the anticipated demand for the mRNA-1273 vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 24, 2020